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Abstract
Objective To assess the economic burden of epithelial ovarian cancer (EOC) in incident patients and the burden by disease 
stage in Spain.
Methods We developed a Markov model from a social perspective simulating the natural history of EOC and its four stages, 
with a 10-year time horizon, 3-week cycles, 3% discount rate, and 2016 euros. Healthcare resource utilization and costs 
were estimated by disease stage. Direct healthcare costs (DHC) included early screening, genetic counselling, medical visits, 
diagnostic tests, surgery, chemotherapy, hospitalizations, emergency services, and palliative care. Direct non-healthcare costs 
(DNHC) included formal and informal care. Indirect costs (IC) included labour productivity losses due to temporary and 
permanent leaves, and premature death. Epidemiology data and resource use were taken from the literature and validated 
for Spain by the OvarCost group using a Delphi method.
Results The total burden of EOC over 10 years was 3102 mill euros: 15.1% in stage I, 3.9% in stage II, 41.0% in stage III, 
and 40.2% in stage IV. Annual average cost/patient was €24,111 and it was €8,641; €14,184; €33,858, and €42,547 in stages 
I–IV, respectively. Of total costs, 71.2% were due to DHC, 24.7% to DNHC, and 4.1% to IC.
Conclusions EOC imposes a significant economic burden on the national healthcare system and society in Spain. Investment 
in better early diagnosis techniques might increase survival and patients’ quality of life. This would likely reduce costs derived 
from late stages, consequently leading to a substantial reduction of the economic burden associated with EOC.
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Introduction
Ovarian cancer (OC) is a rare disease but with a high mor-
tality rate in women [1]. In 2012, the estimated number of 
new cases in Europe was 65,538 and accounted for a total 
of 42,716 deaths [2]. That year, the incidence and mortality 
of OC in Spain were estimated between 13.7 and 7.9 per 
100,000 population, being the fifth most frequent cancer 
type in women and the sixth leading cause of mortality [1].
It is a heterogeneous disease and has many histologi-
cal subtypes; however, the majority of cases (~90%) are of 
epithelial origin (EOC) [3]. The cause of OC is unknown, 
but many associated risk factors have been identified. It 
is predominantly a disease diagnosed in postmenopausal 
women with the majority of cases (> 80%) being diagnosed 
in women over 50 years [3]. A woman’s reproductive his-
tory appears to contribute significantly to her risk of ovarian 
cancer, although the family history also plays an important 
role. Approximately, 11–15% of OC are associated with 
inherited predisposition, mainly related to germline muta-
tions in BRCA1/2 genes [4]. Age also constitutes a risk fac-
tor in those OC patients with BRCA1/2 mutations, with the 
mean age of onset being significantly earlier in those with a 
BRCA1 mutation (45 years) compared with over 60 years of 
age for those with a BRCA2 mutation [5].
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Due to the non-specific symptomatology of the onset 
and despite continuous advances in hereditary OC identi-
fication to prevent it, most patients (75%) [6, 7] are diag-
nosed with an advanced stage of disease according to the 
International Federation of Gynaecology and Obstetrics 
(FIGO) classification [8]. Staging is related to survival 
and is the most important factor to assess the prognosis of 
the patient. According to the FIGO Annual Report, women 
diagnosed with EOC between 1999 and 2001, had a 5-year 
survival mean rate of 86.4% among those diagnosed at 
stage I, 69.9% for those at stage II, 34.3% at stage III, and 
18.6% for those diagnosed at stage IV [9].
EOC has a major impact on patients’ quality of life and 
implies an important economic burden for healthcare ser-
vices, patients, and society in general, for several reasons. 
These patients are treated with a large and growing amount 
of healthcare resources such as hospitalizations, medical 
appointments, and chemotherapy treatments administrated 
in day hospital units, since they are diagnosed [10, 11]. 
Administration is usually expensive, not only because of 
medical resource consumption, but also because it requires 
time expenditure from experienced nurses on day hospital 
units [9, 12, 13]. Additionally, the own aetiology of the 
disease entails a high risk of hospitalization [14]. Also, 
women diagnosed with EOC are usually of working age, so 
labour productivity losses due to premature mortality and 
to permanent and temporary leaves are, therefore, deemed 
considerable [15, 16]. In addition, patients in their last 
stages are likely to require home care, usually provided 
by family members [17]; professional care and support 
activities provided by informal caregivers have a relevant 
opportunity cost, which from a societal perspective should 
be accounted for.
Despite the considerable costs described above, the eco-
nomic burden of EOC from a societal perspective had been 
scarcely analysed in the international literature and, spe-
cifically, in Spain. Measuring this burden may be relevant 
for healthcare decision makers, as it provides useful infor-
mation to assess the real magnitude of the benefits derived 
from the possible intervention programs and health strate-
gies targeting the disease. Moreover, it offers a baseline 
for prevention policy planning, and health resources and 
social care allocation.
Therefore, the main objective of this study was to assess 
the economic burden of EOC in incident patients in Spain, 
as well as the burden by disease stage. It provides essential 
evidence about resource cost, their evolution over time, 
and the efficiency of new treatments at each disease stage 
for economic evaluations. The secondary objective was to 
raise awareness about the importance of this cancer among 
society and healthcare authorities.
Methods
A Markov model was considered as the most appropriate 
method to simulate the progression of EOC, regarding the 
modelling approaches adopted in the previous economic 
studies and the nature of the disease [18, 19]. A societal 
perspective was adopted and only incident cases of EOC 
in Spain were included.
Epidemiology data, survival rates, healthcare resources 
used, personal care (formal and informal), and produc-
tivity losses to populate the model were obtained from a 
literature review, including international and national ref-
erences. International data were used whenever local data 
were not available. Databases consulted were Medline/
Pubmed, Embase, Medes, American Economic Associa-
tion’s Electronic Bibliography (EconLit), and other official 
databases.
All extracted data were afterwards contrasted and vali-
dated through a multidisciplinary expert group using the 
Delphi methodology. This included one individual online 
survey and two in-person meetings to reach final consen-
sus. The OvarCost Expert Panel was composed of a gynae-
cologic oncologist, a clinical oncologist, a genetic counsel-
ling specialist, an oncology hospital pharmacist, a health 
economics specialist, and an epidemiologist involved in 
cancer management at regional and national level.
The Markov model was developed with three possible 
health states: stable, post-progression, and death (Fig. 1). 
The time horizon of the model was 10 years, which is 
enough considering the survival rate of the disease and 
all the cost and clinical consequences for all four stages. 
The cycle length used was 3 weeks (21 days), which is 
the length of a chemotherapy cycle. Patients entered the 
model after they were diagnosed with EOC in the stable 
state. A cycle after, they can either remain stable, become 
worse, and move to a post-progression state, or die. Those 
who progress remain in a post-progression state until they 
die. Mortality risk in patients may change depending on 
their health state (stable or post-progression) and their 
disease stages (I, II, III, and IV) (Fig. 1). It is considered 
that patients are allocated to a specific disease stage at the 
initial diagnosis, and it does not change throughout their 
disease.
Population
Incident patients were estimated from years 2017 to 2026, 
using a linear model between 2015, 2020, and 2025 as per 
GLOBOCAN predictions [1]. Accordingly, 3497 women 
diagnosed with ovarian cancer were estimated for the first 
year, and as per epidemiology data, the majority of cases 
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Fig. 1  Markov model structure 
i disease stages I, II, III, or IV. 
Prssi probability of remaining 
in “stable” state (Stage i), Pdssi 
probability of dying in “stable” 
state (Stage i), Ppssi probability 
to progress from “stable” state 
(Stage i), Prpsi probability of 
remaining in “post-progression” 
state (Stage i), and Pdpsi prob-
ability of dying in “post-pro-
gression” state (Stage i)
Table 1  Epidemiology, patient 
characteristics, and treatment of 
EOC by disease stage
*Own elaboration based on Heintz et al. [9]
EOC, epithelial ovarian cancer
Stage I Stage II Stage III Stage IV
Epidemiology of EOC
EOC incidence (n, (% of total)) 1155 (37%) 195 (6%) 1116 (35%) 681 (22%)
Median progression-free survival (years)* 18.33 6.25 2.00 1.60
Median overall survival (years)* 19.50 7.50 3.20 1.90
Patient characteristics
Mean age at diagnosis (years) 57.4 62.4 64.9 68.1
Mean weight (kg) 65 67 65 66
Mean height (cm) 159 160 159 160
Hospitalizations and emergencies every 6 months
Number of hospitalizations 1.2 1.2 2.1 2.1
Patients hospitalized (%) 15.4 15.4 48.2 48.2
Number of emergencies 1.5 1.5 1.7 1.7
Patients in emergency services (%) 23.1 23.1 22.2 22.2
Treatment
None 0% 0% 3.10% 8.80%
Surgery 66.70% 19.80% 11.30% 8.80%
Neoadjuvant chemotherapy + surgery 0% 0% 14.40% 24.20%
Surgery + adjuvant chemotherapy 33.30% 80.20% 71.10% 58.20%
Type of surgery
Laparotomy 100% 100% 100% 100%
Omentectomy 0% 6.38% 100% 100%
Abdominal total hysterectomy 100% 100% 100% 100%
Bilateral salpingo-oophorectomy 0% 100% 100% 100%
Lymphadenectomy 0% 0% 75% 100%
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(90%) are of epithelial origin [3]. Those were distributed 
by the four disease stages [20], as shown in Table 1. New 
cases diagnosed in the following years until 2026 were 
added each year assuming no changes in the distribution of 
disease stages over time. Incident patients’ distribution by 
stage comes from population-based cancer registries [20].
Transition probabilities
Transition probabilities depend on the disease stage assigned 
at diagnosis and the health state as patients enter the model. 
Death probability in the stable state (Pdss) was the mortal-
ity rate in the general Spanish female population [21] (Pnd, 
natural death probability). This mortality rate was estimated 
taking into account age at diagnosis and at each stage of the 
disease [15], as stated in Table 1, and its evolution over time; 
finally, it was transformed to probabilities as 1 − exp(rate at 
age).
Transition probabilities from stable state to post-progres-
sion state (Ppss) (Eq. 1) were assessed by progression-free 
survival (PFS) curves for each disease stage, which were 
built based on an exponential distribution of median PFS 
(Table 1; Fig. 2a) [9].
Equation 1. Probability of transitioning from stable to 
post-progression state:
Transition probabilities of patients who remain stable 
(Prss) were calculated as the inverse of the probability of 
dying plus the transition probability of progressing from 
stable to post-progression state. Transition probabilities 
from post-progression to death (Pdps) were estimated as 
the difference between overall survival (OS) and PFS, plus 
the probability of natural death (Eq. 2) (Fig. 2b). OS curves 
were built using an exponential distribution, taking into 




account the median OS at each stage published by Heintz 
et al. [9] (Table 1; Fig. 2b).
Equation 2. Probability of dying for patients at post-pro-
gression state (Pdps):
Transition probabilities of the patients who remain at the 
post-progression state (Prps) were estimated as the inverse 
of the probability of dying for patients at post-progression 
state.
Costs and resource use
Costs were expressed in 2016 Euros (Tables 1, 2 in Online 
Resource). Unit healthcare costs were the median value of 
the unit costs for each Autonomous Community in Spain 
[20–37]. Since the costs come from different years, they 
were updated to € 2016 using the corresponding inflation 
rate: a medicine consumer price index (CPI) of 0.77% for 
direct healthcare costs (DHC) [40] (except for pharmaceuti-
cal costs and tariffs from Autonomous Communities already 
actualised) and a general CPI increase of 1.97% for direct 
non-healthcare costs (DNHC) [40]. In the Markov model, 
the costs were discounted at an annual rate of 3%, accord-
ing to Spanish health technology assessment recommenda-
tions [41]. An annual growth rate of 1% was considered for 
labour productivity loss [42]. The average annual cost per 
patient was assessed dividing the total cost by the number of 
patients (those who were alive at the beginning of the year 
plus the incident patients in that year). Model costs were 
categorised as DHC, DNHC, and indirect costs (IC).
DHC included diagnosis and follow-up tests, treatments, 
and palliative care. Testing required at diagnosis according 
to the Spanish Society of Gynaecology and Obstetrics [12] 
include ovarian biopsy, biochemical analysis and vaginal 
ultrasonography, among others. Regarding selection criteria 
(2)








Fig. 2  Survival curves by disease stage. Progression free survival (a) and overall survival (b)
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to identify BRCA mutation, it was agreed by the panel group 
that 20% of patients with EOC are referred to BRCA1/2 
genetic test and genetic counselling, accounting two of these 
visits, before and after the test [43]. Of these patients, 5% 
are identified with the genetic mutation and an average of 
five family members are derived to genetic counselling [44], 
a transvaginal ultrasound and a blood test every 6 months 
to detect the tumour marker CA125 [43]. The patient’s fol-
low-up depends on their disease state. The frequency for 
follow-up testing may be lower in stable patients, depending 
on the period of time that they remain at this health estate 
[12]. The percentage of patients hospitalized and those who 
attend to the emergency department due to EOC were also 
considered by disease stage (Table 1) [14]. Treatment man-
agement depends on many factors, such as the spread of the 
tumour and the patient’s clinical situation, being surgery or/
and chemotherapy the standard of care [3, 9]. Treatment 
usually starts with the surgical excision of the tumour mass. 
Nevertheless, this procedure is not always possible and an 
interval debulking surgery is performed. This intervention is 
a surgical excision that takes place after patients have taken 
neoadjuvant chemotherapy [12]. Most patients receive adju-
vant chemotherapy. However, patients in stages Ia and Ib do 
not need chemotherapy after surgery and only remain under 
clinical observation [12]. The type of surgery depends on 
the size and the spread of the tumour, and on whether or not 
the woman is planning to get pregnant in the future [12, 13].
Clinical experts panel classified chemotherapy as: (1) 
neoadjuvant: patients who receive 3 cycles of paclitaxel in 
combination with carboplatin before surgery and complete 
their treatment with other 3 cycles of chemotherapy [12]; 
(2) adjuvant: chemotherapy administered after surgery in 
the stable state (stages I, II, and III); (3) post-progression: 
chemotherapy administered at the post-progression state 
(stages I and II); and (4) advanced: chemotherapy admin-
istered at the post-progression states at stage III and at both 
states at stage IV (Table 1).
The recommended drugs used are based on the EOC 
treatment recommended by SEGO guidelines [12]: pacli-
taxel, carboplatin, doxorubicin, bevacizumab, cisplatin, 
gemcitabine, topotecan, trabectedin, and docetaxel. Its usage 
was accounted based on its market share [45]. Doses were 
calculated according to the usual clinical practice and prod-
uct labels [46–54] (Table 4 in Online Resource). Dose of 
carboplatin [47] was determined using the Calvert formula 
[55]. Du Bois et Du Bois formula was used to calculate the 
body surface area when necessary [56] (Table 3 in Online 
Resource). Patients’ height and weight were consulted in 
Spanish National Health Survey according to the mean age 
at diagnosis of each stage disease [15, 57] (Table 1). Drug 
costs were calculated using the list price (LP) [58], including 
Royal Decree Law 8/2010 deduction rate, when necessary, 
and a 4% of the value-added tax (VAT) entitled for Spain 
[58–61]. For intravenous drugs, the model also considered 
non-vials optimization and the cost of administration for 
each drug (€0.32 per minute [62]): time of administration 
required for each one [46–53] in the day hospital plus the 
cost of the 30-min preparation (Table 3 in Online Resource).
Palliative care is given to the patients in their last 48 days 
of life [63]. Up to 93.3% of the patients receive follow-up 
care at outpatient hospitals, while the remaining (6.7%) are 
assisted by palliative home care team [64]. Patients need a 
mean of 9.5 home visits of palliative-care services, while 
those who receive follow-up at the outpatient hospital are 
seen by a nurse [63]. In both cases, patients also pay four 
visits, on average, to the primary-care doctor [63] and they 
spent their terminal phase of their illness at home (59.6%) or 
at the hospital (40.4%) [65]. The last 3 days of this terminal 
phase, patients stay at home [66], and they are visited twice 
a day by a nurse [67]. Of these, 14% receive sedation [66]. 
The costs of visits [22–39] and drugs used in the palliative-
care phase were also considered [58–61, 68–71] (Tables 1, 
4 in Online Resource).
DNHC considered were formal care costs (i.e., profes-
sional care financed by private or public funds) and informal 
care costs given at home (non-remunerated care from rela-
tives or friends). Based on the literature, it was assumed that 
17.4% of the patients received private care, 9.5% public care 
[63], and 93.4% received informal care [72] throughout their 
last 48 days of life [63]. On average, it was considered that 
public caregivers spent 1.5 h providing care [63], private 
caregivers 8 h [63], and informal caregivers 10.3 h [17]. 
According to the proxy good method [73], hourly wage for 
formal and informal caregivers was equally valued, €13.56 
[74].
Lost labour productivity due to temporary or permanent 
leave and premature death were included as indirect costs 
(IC), using the human-capital method [75–78]. At some 
point in the progress of the disease, patients with EOC 
become unable to develop their labour activities [79, 80]. 
Overall, 30% of stable patients lose 60 days due to tem-
porary leave, while the remaining 70% lose over 70 days 
[45]. It was assumed that at advanced stages, patients are on 
sick leave, since progression starts until age of retirement 
(65 years). In case the patient’s death occurs before 65 years, 
sick leave period is assumed to last between the beginnings 
of the disease progression until patient dies. Patients on 
sick leave for more than 1 year were considered to be in 
permanent leave [81]. Labour productivity loss caused by 
premature death included lost productivity of patients who 
die before 65 years of age [21, 79, 82, 83]. The percentage 
of women employed and their respective salaries are used 
to estimate labour productivity losses (Table 5 in Online 
Resource).
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Sensitivity analysis
Deterministic and univariate sensitivity analyses, including 
ten different scenarios, were conducted to examine the mod-
el’s robustness. According to the OvarCost Expert Panel, 
different scenarios were built based on the possible varia-
tion of the most sensitive parameters: percentage of patients 
who receive genetic counselling (from 35 to 70%), patients 
weight (± 10%), growth productivity discount rate on (from 
0 to 2%), manufacturer’s drug price (− 10%), discount drug 
rate (from 0 to 6%), tests and medical visits cost (maximum 
and minimum prices in the Autonomous Communities), age 
at time of diagnosis (± 10%), bevacizumab dose recommen-
dation (7.5 mg/kg), caregiver’s salary/informal care assess-
ment per hour (€7.5) [84], and informal care hours received 
(± 30%).
Results
The total economic burden of EOC in Spain was estimated 
in 3102 million euros (mill€) in 10 years. Stages I and II 
represented around 19% of the total cost of the disease each 
year, while stages III and IV accounted for 41 and 40%, 
respectively (Table 2). The average annual cost per patient 
was €24,111, being the greatest cost the corresponding to 
patients in stage disease IV (€42,547). By cost type, most 
of the economic burden of EOC was due to DHC (71.2%) 
being the DNHC 24.7% and IC 4.1% of the total, since most 
patients are diagnosed over 40 years of age. However, IC are 
more relevant at early stages (23.2% at stage I and 7.2% at 
stage II) (Fig. 3a; Table 2).
DHC were estimated in 2208 mill€ in 10 years. The aver-
age annual cost per patient was €17,501. The most important 
cost categories were advanced chemotherapy (909.9 mill€), 
hospitalizations (812.5 mill€), and surgery (204.0 mill€). 
Together, these represented around 87.2% of DHC. The 
average annual cost per patient was €6657.6 for advanced 
chemotherapy; €6304.1 for hospitalizations, and €2024.6 
for surgeries (Table 2). Average annual costs per patient 
increased as the cancer spread, with DHC at stage IV being 
around eight times higher than DHC at stage I (Fig. 3b).
DNHC represented 766.7 mill€ in 10 years. The average 
annual cost per patient was €5608. Patients at stages II, III, 
and IV were substantially assisted by informal carers. Infor-
mal care implied 98.6% of DNHC at any stage (Table 2) and 
reached €12,437.4 per patient per year at stage III (Fig. 3c).
Lost labour productivity was estimated in 127 mill€ in 
10 years, of which temporary leave accounted for 40.9%; 
permanent leave for 5.4%, and premature death for 53.7%. 
Most losses occurred at early disease stage, with 85.5% in 
stage I (Fig. 3d). Labour productivity losses amounted to 
€1002.1 per patient every year. IC annual per patient was 
€1990.6 at stage I and €1198.1 at stage II. However, a lower 
productivity cost was observed for patients at stages III and 
IV (€342.9 at stage III and € 0 at stage IV) (Table 2).
Sensitivity analysis
The sensitivity analysis was based on the percentage of 
patients who receive genetic counselling, patients weight, 
discount rate on growth productivity, and manufacturer price 
had almost no impact on the global burden of the disease 
(changed the average annual cost per patient in between 
− 2.9 and 2.6%).
Figure 4 shows sensitivity analysis results which substan-
tially modified the global study results. The average annual 
cost per patient (€24,111) fluctuates between €21,151 and 
€28,281, which influences the global burden between 2605 
and 3734 mill€ in 10 years, being in the base case analysis 
3102 mill€.
Discussion
To our knowledge, this is the first study that is close to esti-
mating the economic impact of EOC in Spain considering 
DHC as well as DNHC and IC involved in patient care. Our 
estimates indicate that the global average cost per patient 
with EOC may amount to €24,111 every year in Spain, with 
significant differences by disease stages, from €8,641 at 
stage I to €42,547 at stage IV. This result was expected as 
most of the patients are diagnosed at advanced stages of 
the disease and those are likely to need more healthcare 
resources and home care.
Research on the economic burden of OC is scarce in sci-
entific literature. However, Kim et al assessed the annual 
DHC per patient in Hungary, Serbia, and Slovakia [18]. 
Their approach was based on different health states: surgi-
cal treatment; first-line, second-line, and third-line chem-
otherapy; and monitoring/follow-up and palliative care/
death. However, we calculated the DHC per stage of dis-
ease, according to the FIGO classification [8]. This latter 
methodology allows estimating the resources that patients 
require, considering their stage at diagnosis. It also makes 
easier the comparison to future studies regarding the burden 
of OC in other countries.
The growing scientific literature on informal care costs 
suggests the relevance of this social resource in the case 
of many diseases and injuries [85, 86]. One of the strong-
est findings of our study is the estimation of informal care 
costs associated with EOC. To our knowledge, this is the 
first study that estimates the economic impact of caregiving 
among EOC patients in Spain. Our results show that costs of 
informal care represent 24.4% of the global burden of EOC, 
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and are higher in stage III. Finally, we found that IC repre-
sent the smallest proportion of the global burden (4.1%), 
and they are significantly higher at early stage of the disease 
(stage I), when women are more likely to be of working age 
and less likely to die prematurely, than at later stages.
Our study is not without limitations. First, due to the lack 
of information about this cancer in Spain, the PFS curves 
from other countries were deemed similar enough to be used 
for our country. In addition, some data referring to all types 
of OC were used, since EOC accounts for 90% of the OC 
Table 2  Results of the model: direct healthcare costs, direct non-healthcare costs, and indirect costs by stage
Stage I Stage II Stage III Stage IV
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in general. Those data were considered representative and 
valid. Second, as neither national nor international refer-
ences were found regarding average height and weight of 
patients with EOC by disease stage, our model included the 
average weight and height of women with any cancer by age 
at diagnosis in Spanish National Health Survey. However, 
the sensibility analysis showed that the weight of the patients 
had almost no impact on the global burden of EOC. Third, 
because of this lack of data availability about the patients in 
Spain, we adopted an incidence model approach. However, 
since this method does not include the patients previously 
diagnosed, and it may underestimate the burden of EOC. 
Fourth, our model considered that vials were used only once, 
although in Spanish practice, patients are usually gathered 
in day hospitals to optimise drug vials usage. Optimization 
of vials would decrease the global cost of treatment. Fifth, 
the percentage of patients who needed informal care was 
obtained from an observational study about patients with 
haematological neoplasia developed in Spain, whose situa-
tion may be different compared to those with EOC. Finally, 
our study does not quantify the substantial psychological 
load that caregivers may suffer from.
Despite its limitations, we believe that this study 
represents the most complete economic burden of EOC 
performed to date in Spain. Our results suggest that the 
disease’s economic impact on healthcare resources sig-
nificantly increases with the stage at which the cancer is 
diagnosed. Investment in the development and evaluation 
of techniques for early diagnosis may imply higher sur-
vivals rates and a substantial reduction in the economic 
burden of EOC, due to possible cost savings at advanced 
disease stages. Besides, this study emphasizes the impor-
tance of informal care in the global burden of the disease, 
especially in advanced stages. In conclusion, our results 
highlight the importance of analysing the economic conse-
quences of EOC from a societal perspective, providing an 
insight into the distribution of this cancer costs by stage, 
with the final aim of informing healthcare services plan-
ning appropriately.
Fig. 3  Cost distribution results by disease stage. Total costs (a), direct healthcare costs (b), direct non-healthcare costs (c) and indirect costs (d)
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